Honglan Wang

Conflicts of Interest The authors declare no conflicts of interest. Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request. Peer Review For transparency, the peer review documents associated with this article are available at https://doi.org/10.1111/jop.70159.

Introduction Dysregulated expression of urokinase-type plasminogen activator (PLAU), a serine protease, is frequently associated with various cancers. However, in oral squamous cell carcinoma (OSCC), the specific biological functions and mechanisms of action of PLAU remain unclear.

Graphical Abstract Targeted Drug Delivery to the Bone Marrow In article number 2409895, Liu Huiwen, Zhiqing Pang, Yu Hu, and co-workers introduce an innovative bone marrow-targeting strategy that utilizes c(RGDfk)-modified liposomes as therapeutic carriers. These liposomes (the cargo) exploit aging neutrophils (the purple cells), known for their intrinsic ability to home to the bone marrow, as natural transport vehicles.